NCT04611256

Mesenchymal Stem Cells in Patients Diagnosed With COVID-19

Status unknown Phase 1 Last updated 12 November 2020

What this trial tests

Phase 1 trial testing MSC in Covid19 in 20 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
30 November 2020

30 December 2020

Quick facts

Lead sponsor	Hospital Reg. Lic. Adolfo Lopez Mateos
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 August 2020
Primary completion	30 November 2020
Estimated completion	30 December 2020
Sites	1 location across Mexico

Drugs / interventions tested

• MSC — full drug profile →
• Control

Conditions studied

• Covid19 — all drugs for Covid19 →

Sponsor

Hospital Reg. Lic. Adolfo Lopez Mateos

Who can join

Adults 18 to 65, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The propose of this study is implement adjuvant therapy with adipose tissue derived-mesenchymal stem cells (MSCs) for critical COVID-19 patients admitted to the intensive care unit of the Regional Hospital Lic. Adolfo López Mateos of the Institute for Social Security and Services for State Workers to reduce cytokine storm and contribute to the favorable resolution of respiratory insufficiency and multiple organic failure.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
   Markov A, Thangavelu L, Aravindhan S, Zekiy AO, et al · · 2021 · cited 174× · PMID 33736695 · DOI 10.1186/s13287-021-02265-1
2. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
   Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1
3. Mesenchymal stem cells and their derived exosomes to combat Covid-19.
   Yousefi Dehbidi M, Goodarzi N, Azhdari MH, Doroudian M. · · 2022 · cited 41× · PMID 34363275 · DOI 10.1002/rmv.2281
4. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review.
   Hussain M, Khurram Syed S, Fatima M, Shaukat S, et al · · 2021 · cited 38× · PMID 34992415 · DOI 10.2147/jir.s334043
5. Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.
   Abdelgawad M, Bakry NS, Farghali AA, Abdel-Latif A, et al · · 2021 · cited 33× · PMID 34419143 · DOI 10.1186/s13287-021-02542-z
6. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
   Chen L, Qu J, Kalyani FS, Zhang Q, et al · · 2022 · cited 31× · PMID 35187617 · DOI 10.1007/s00018-021-04096-y
7. The Clinical Trials of Mesenchymal Stromal Cells Therapy.
   Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
8. Human Mesenchymal Stem/Stromal Cells in Immune Regulation and Therapy.
   Mezey É. · · 2022 · cited 28× · PMID 35298659 · DOI 10.1093/stcltm/szab020